AndhraNews.net
Home » Business News » 2015 » October » October 28, 2015

MedX Health Corp. Announces Proposed Debt Settlements


October 28, 2015 - Mississauga, ON

MISSISSAUGA, ON--(Marketwired - October 28, 2015) - MedX Health Corp. (TSX VENTURE: MDX), announces that it has entered into agreements to settle a total of $406,564.96 of debt owed to certain trade creditors and insider creditors, subject to all relevant consents and approvals. Under the Debt Settlement Agreements, a total of $77,609.25 of trade debt will be settled by issuance of 703,437 shares issued at prices between $0.10 and $0.25 per share and $328,955.71 of debt due to creditors who are insiders or are related to insiders will be settled by issuance of 2,550,000 shares issued at prices between $0.10 and $0.16 per share. Regulatory and other consents will include approval from the TSX Venture Exchange and, in relation to shares issuable to insiders and creditors related to insiders, approval of shareholders (excluding votes of shares owned by the relevant insiders).

MedX presently has 70,637,072 common shares issued and outstanding.

About MedX.

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer; it manufactures and distributes SIMSYS™ and MoleMate™, hand-held devices that use patented technology utilizing light and its remittance to view beneath suspicious moles and lesions in a pain free, non-invasive manner, creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in drugstore settings where the images are sent remotely to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia and Europe. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information:
Rob von der Porten
Chief Executive Officer
MedX Health Corp
investor@medxhealth.com
Phone: (905) 670-4428

MarketWire

Comment on this story

Share